PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo r&d expenses
Research and development expenses are spending on new products and technology.
Perrigo's R&D Expenses for the twelve months ending Sep 26, 2026 was $92.00M, down 9.3% year over year. For fiscal 2025 it was $95.40M, down 15.0% from the year before. Over ten years it grew -4.6% a year on average. The highest annual figure on record is $218.60M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.40M | -15.0% |
| FY2024 | Dec 31, 2024 | $112.20M | -8.4% |
| FY2023 | Dec 31, 2023 | $122.50M | -0.5% |
| FY2022 | Dec 31, 2022 | $123.10M | +0.9% |
| FY2021 | Dec 31, 2021 | $122.00M | +0.2% |
| FY2020 | Dec 31, 2020 | $121.70M | +2.1% |
| FY2019 | Dec 31, 2019 | $119.20M | -45.5% |
| FY2018 | Dec 31, 2018 | $218.60M | +30.4% |
| FY2017 | Dec 31, 2017 | $167.70M | -10.7% |
| FY2015 | Jun 27, 2015 | $187.80M | +23.1% |
| FY2014 | Jun 28, 2014 | $152.50M | +32.4% |
| FY2013 | Jun 29, 2013 | $115.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | $21.90M | -12.0% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $23.70M | +7.7% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $24.60M | -7.9% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $21.80M | -21.6% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $24.90M | -4.2% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $22.00M | -25.2% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $26.70M | -7.9% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $27.80M | -6.1% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $26.00M | -12.2% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $29.40M | -8.7% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $29.00M | -6.8% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $29.60M | -9.2% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $29.60M | -0.7% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $32.20M | +2.2% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $31.10M | +6.1% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $32.60M | +7.6% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $29.80M | +8.0% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $31.50M | -4.5% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $29.30M | -5.8% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $30.30M | -8.2% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $27.60M | -9.2% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $33.00M | +8.6% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $31.10M | +11.5% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $33.00M | -44.4% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $30.40M | -30.9% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $30.40M | -30.8% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $27.90M | -30.6% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $59.40M | +33.2% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $44.00M | +0.7% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $43.90M | -52.2% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $40.20M | +4.7% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $44.60M | -4.9% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $43.70M | +13.8% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $91.90M | +115.7% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $38.40M | -3.5% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $46.90M | -25.1% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $38.40M | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $42.60M | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $39.80M | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $62.60M | – |
See a number that looks wrong?